首页> 外文期刊>Translational psychiatry. >Clozapine modifies the differentiation program of human adipocytes inducing browning
【24h】

Clozapine modifies the differentiation program of human adipocytes inducing browning

机译:氯氮平改变人脂肪细胞诱导褐变的分化程序

获取原文
           

摘要

Administration of second-generation antipsychotic drugs (SGAs) often leads to weight gain and consequent cardio-metabolic side effects. We observed that clozapine but not six other antipsychotic drugs reprogrammed the gene expression pattern of differentiating human adipocytes ex vivo , leading to an elevated expression of the browning marker gene UCP1 , more and smaller lipid droplets and more mitochondrial DNA than in the untreated white adipocytes. Laser scanning cytometry showed that up to 40% of the differentiating single primary and Simpson–Golabi–Behmel syndrome (SGBS) adipocytes had the characteristic morphological features of browning cells. Furthermore, clozapine significantly upregulated ELOVL3 , CIDEA , CYC1 , PGC1A and TBX1 genes but not ZIC1 suggesting induction of the beige-like and not the classical brown phenotype. When we tested whether browning induced by clozapine can be explained by its known pharmacological effect of antagonizing serotonin (5HT) receptors, it was found that browning cells expressed 5HT receptors 2A, 1D, 7 and the upregulation of browning markers was diminished in the presence of exogenous 5HT. Undifferentiated progenitors or completely differentiated beige or white adipocytes did not respond to clozapine administration. The clozapine-induced beige cells displayed increased basal and oligomycin-inhibited (proton leak) oxygen consumption, but these cells showed a lower response to cAMP stimulus as compared with control beige adipocytes indicating that they are less capable to respond to natural thermogenic anti-obesity cues. Our data altogether suggest that novel pharmacological stimulation of these masked beige adipocytes can be a future therapeutic target for the treatment of SGA-induced weight gain.
机译:服用第二代抗精神病药(SGA)通常会导致体重增加和随之而来的心代谢不良反应。我们观察到,氯氮平而不是其他六种抗精神病药物重新编程了离体分化人类脂肪细胞的基因表达模式,与未处理的白色脂肪细胞相比,导致褐变标记基因UCP1的表达升高,脂质滴和线粒体DNA越来越多。激光扫描细胞计数法显示,高达40%的分化单原发性和Simpson-Golabi-Behmel综合征(SGBS)脂肪细胞具有褐变细胞的特征形态特征。此外,氯氮平显着上调ELOVL3,CIDEA,CYC1,PGC1A和TBX1基因,但不上调ZIC1,表明诱导了米色样而不是经典的棕色表型。当我们测试氯氮平诱导的褐变是否可以通过其拮抗5-羟色胺(5HT)受体的已知药理作用来解释时,发现褐变细胞表达5HT受体2A,1D,7,并且在存在HT的情况下褐变标记的上调被减弱了。外源5HT。未分化的祖细胞或完全分化的米色或白色脂肪细胞对氯氮平的给药没有反应。氯氮平诱导的米色细胞显示出增加的基础和寡霉素抑制(质子泄漏)的耗氧量,但与对照米色脂肪细胞相比,这些细胞对cAMP刺激的反应较低,表明它们对自然生热肥胖症的反应能力较弱提示。我们的数据完全表明,这些被掩盖的米色脂肪细胞的新型药理刺激可能是治疗SGA引起的体重增加的未来治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号